Pulmonary arterial hypertension related to HIV infection: Improved hemodynamics and survival associated with antiretroviral therapy

Clinical Infectious Diseases

Volumn 38, Issue 8, 2004, Pages 1178-1185

  Zuber, Jean Philippe ^a   Calmy, Alexandra ^b   Evison, John M ^c   Hasse, Barbara ^a   Schiffer, Veronique ^b   Wagels, Thomas ^d   Nuesch, Reto ^e   Magenta, Lorenzo ^f   Ledergerber, Bruno ^a   Jenni, Rolf ^a   Speich, Rudolf ^a   Opravil, Milos ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b University Hospital and Medical Faculty of Geneva   (Switzerland)

^c Canton of Bern   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f Univ and Cant Hospital of Lugano   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ILOPROST; NUCLEOSIDE DERIVATIVE; PROSTACYCLIN; VASODILATOR AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE PRESSURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LONG TERM CARE; MALE; MORTALITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; DRUG EFFECT; SURVIVAL RATE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD PRESSURE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 2342479992     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383037     Document Type: Article

References (42)

1. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 1994; 89:2722-7.
2. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991; 100:1268-71.
3. Himelman RB, Dohrmann M, Goodmann P, et al. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. Am J Cardiol 1989; 64:1396-9.
4. Coplan NL, Shimony HL, Joachim JR, et al. Primary pulmonary hypertension associated with human immunodeficiency viral infection. Am J Med 1990; 89:96-9.
5. Seoane L, Shellito J, Welsh D, DeBoisblanc PB. Pulmonary hypertension associated with HIV infection. South Med J 2001; 94:635-9.
6. Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998; 73:37-45.
7. Pellicelli AM, Barbaro G, Palmieri F, et al. Primary pulmonary hypertension in HIV patients: a systematic review. Angiology 2001; 52: 31-41.
8. Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987; 18:1293-6.
9. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7.
10. Mette SA, Palevsky HI, Pietra GG, et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection: a possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992; 145:1196-200.
11. Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic endothelin-1 production by HIV-I glycoprotein 120. J Immunol 1993; 150:4601-9.
12. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11: 554-9.
13. Tuder RM, Weinberg A, Bates TO, Hoeper MM, Zhang L, Voelkel NF. tat-protein of HIV enhances inflammatory cell binding and PDGF levels in CMV-infected endothelial cells [abstract 2237]. Circulation 1994; 90(Suppl I):417.
14. Voelker NF, Tuder NM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-38.
15. Morse JH, Barst RJ, Itescu S, et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med 1996; 153:1299-301.
16. Pietra GG, Edwards WD, Kay M, et al. Histopathology of primary pulmonary hypertension. Circulation 1989; 80:1198-206.
17. Polos PG, Wolfe D, Harley RA, Strange C, Sahn SA. Pulmonary hypertension and human immunodeficiency virus infection: two reports and a review of the literature. Chest 1992; 101:474-8.
18. Opravil M, Sitbon O, Gressin V, et al. Safety and efficacy of bosentan in pulmonary arterial hypertension associated with HIV infection [abstract 1007]. Antivir Ther 2003;8(Suppl 1):S469.
19. Rubin LJ, Badesch DB, Bobyn JB, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
20. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-8.
21. Metha NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hypertension. Chest 2000; 118:1133-41.
22. Golpe R, Fernantes-Infante B, Fernandez-Rozas S. Primary pulmonary hypertension associated with immunodeficiency virus infection. Postgrad Med J 1998; 74:400-4.
23. Klings ES, Farber HW. Current management of primary pulmonary hypertension. Drugs 2001; 61:1945-56.
24. Opravil M, Pechère M, Speich R, et al. HIV-associated primary pulmonary hypertension: a case control study. Am J Respir Crit Care Med 1997; 155:990-5.
25. Louis M, Thorens JB, Chevrolet JC. Calcium-channel blockers (CCB) testing for primary pulmonary hypertension (PPH) associated with HIV infection [abstract]. Am Rev Respir Dis 1993; 147:A536.
26. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162:1846-50.
27. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167:1433-9.
28. Stricker H, Domenighetti G, Mombelli G. Prostacyclin for HIV-associated pulmonary hypertension [letter], Ann Intern Med 1997; 127: 1043.
29. Schuhmacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15:1747-8.
30. Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002; 16:1568-9.
31. Pellicelli AM, Palmiere F, D'Ambrosio G, et al. Role of human immunodeficiency virus in primary pulmonary hypertension: case reports. Angiology 1998; 49:1005-11.
32. Speich R, Jenni R, Opravil M, Jaccard R. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly 2001; 131:663-5.
33. Petureau F, Escamilla R, Hermant C, Mourlanette P, Berjaud J, Krempf M. Pulmonary artery hypertension in HIV seropositive drug addicts: apropos of 10 cases. Rev Mal Respir 1998; 15:97-102.
34. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000; 40:282-4.
35. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler- catheterization study in 127 patients. J Am Coll Cardiol 1985; 6:750-6.
36. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
37. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30.
38. Pantaleo G. New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995; 13:487-512.
39. Pellicelli AM, Palmieri F, Cicalini S, Petrosillo N. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci 2001; 946:82-94.
40. Bisset LR, Cone RW, Huber W, et al. Highly active anti-retroviral therapy during early HIV-infection reverses T-cell activation and maturation abnormalities. AIDS 1998; 12:2115-23.
41. Cool CD, Rai PR, Yeager ME, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349: 1113-22.
42. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384-90.